Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

How I treat anaplastic glioma without 1p/19q codeletion.

Berghoff A, van den Bent M.

ESMO Open. 2019 Aug 20;4(Suppl 2):e000534. doi: 10.1136/esmoopen-2019-000534. eCollection 2019. Review.

2.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, RudĂ  R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

3.

Anaplastic astrocytoma.

Grimm SA, Chamberlain MC.

CNS Oncol. 2016 Jul;5(3):145-57. doi: 10.2217/cns-2016-0002. Epub 2016 May 27. Review.

4.

The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.

Hacisalihoglu P, Kucukodaci Z, Gundogdu G, Bilgic B.

Turk Neurosurg. 2017;27(5):682-689. doi: 10.5137/1019-5149.JTN.16832-15.1.

5.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

6.

Anaplastic gliomas in adults: an update.

Izquierdo C, Joubert B, Ducray F.

Curr Opin Oncol. 2017 Nov;29(6):434-442. doi: 10.1097/CCO.0000000000000409. Review.

PMID:
28901965
7.

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Lecavalier-Barsoum M, Quon H, Abdulkarim B.

Cochrane Database Syst Rev. 2014 May 15;(5):CD007104. doi: 10.1002/14651858.CD007104.pub2. Review.

PMID:
24833028
8.

[Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].

Wick W, Weller M.

Nervenarzt. 2010 Aug;81(8):928-30, 932-5. doi: 10.1007/s00115-010-2956-1. Review. German.

PMID:
20635074
9.

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).

Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY.

Cancer Res Treat. 2019 Oct 28. doi: 10.4143/crt.2019.421. [Epub ahead of print]

10.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

11.

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.

Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.

J Neurooncol. 2015 Sep;124(2):197-205. doi: 10.1007/s11060-015-1822-1. Epub 2015 Jun 2.

PMID:
26033545
12.

Anaplastic glioma: current treatment and management.

Le Rhun E, Taillibert S, Chamberlain MC.

Expert Rev Neurother. 2015 Jun;15(6):601-20. doi: 10.1586/14737175.2015.1042455. Epub 2015 May 2. Review.

PMID:
25936680
13.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

14.

Anaplastic glioma.

Paleologos NA, Merrell RT.

Curr Treat Options Neurol. 2012 Aug;14(4):381-90. doi: 10.1007/s11940-012-0177-6.

PMID:
22665140
15.

Grade II and III Oligodendroglioma and Astrocytoma.

van den Bent MJ, Chang SM.

Neurol Clin. 2018 Aug;36(3):467-484. doi: 10.1016/j.ncl.2018.04.005. Epub 2018 Jun 15. Review.

PMID:
30072066
16.

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.

Abrunhosa-Branquinho AN, Bar-Deroma R, Collette S, Clementel E, Liu Y, Hurkmans CW, Feuvret L, Van Beek K, van den Bent M, Baumert BG, Weber DC.

Radiother Oncol. 2018 May;127(2):292-298. doi: 10.1016/j.radonc.2018.03.013. Epub 2018 Mar 29.

17.

1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.

Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.

Neuro Oncol. 2013 Jun;15(6):775-82. doi: 10.1093/neuonc/not027. Epub 2013 Mar 13.

18.

Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM.

Neuro Oncol. 2017 Feb 1;19(2):242-251. doi: 10.1093/neuonc/now176.

19.

1p/19q codeletion and RET rearrangements in small-cell lung cancer.

Lu H, Xu H, Xie F, Qin J, Han N, Fan Y, Mao W.

Onco Targets Ther. 2016 Jun 16;9:3571-7. doi: 10.2147/OTT.S108781. eCollection 2016.

20.

Treatment of anaplastic glioma.

Wick W, Wiestler B, Platten M.

Cancer Treat Res. 2015;163:89-101. doi: 10.1007/978-3-319-12048-5_6. Review.

PMID:
25468227

Supplemental Content

Support Center